Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 2 |
2023 | 3 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.
Cancers (Basel). 2023 Jun 27;15(13):3364. doi: 10.3390/cancers15133364.
Cancers (Basel). 2023.
PMID: 37444475
Free PMC article.
Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
Siebert N, Zumpe M, Schwencke CH, Biskupski S, Troschke-Meurer S, Leopold J, Zikoridse A, Lode HN.
Siebert N, et al.
Cancers (Basel). 2023 Jun 23;15(13):3317. doi: 10.3390/cancers15133317.
Cancers (Basel). 2023.
PMID: 37444427
Free PMC article.
Item in Clipboard
Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.
Troschke-Meurer S, Zumpe M, Meißner L, Siebert N, Grabarczyk P, Forkel H, Maletzki C, Bekeschus S, Lode HN.
Troschke-Meurer S, et al.
Cancers (Basel). 2023 Jan 31;15(3):904. doi: 10.3390/cancers15030904.
Cancers (Basel). 2023.
PMID: 36765861
Free PMC article.
Item in Clipboard
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments.
Klingel L, Siebert N, Troschke-Meurer S, Zumpe M, Ehlert K, Huber S, Loibner H, Mutschlechner O, Lode HN.
Klingel L, et al.
Cancers (Basel). 2022 Nov 25;14(23):5802. doi: 10.3390/cancers14235802.
Cancers (Basel). 2022.
PMID: 36497290
Free PMC article.
Item in Clipboard
The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta.
Siebert N, Leopold J, Zumpe M, Troschke-Meurer S, Biskupski S, Zikoridse A, Lode HN.
Siebert N, et al.
Cancers (Basel). 2022 Oct 4;14(19):4842. doi: 10.3390/cancers14194842.
Cancers (Basel). 2022.
PMID: 36230765
Free PMC article.
Item in Clipboard
Cite
Cite